AEON Biopharma, Inc. (AEON) Form S-1 — Jul 8, 2026
AEON Biopharma has filed an S-1 registration statement for a public offering of 17,479,373 shares of common stock at an assumed price of $0.7151 per share to fund operations and the development of ABP-450, a biosimilar to BOTOX. The offering structure includes aggressive terms such as 200% warrant coverage, consisting of two-year and five-year milestone warrants, and a 15% over-allotment option for underwriters Lake Street Capital Markets and Laidlaw & Company. The company estimates net proceeds of approximately $11.0 million, increasing to $12.8 million if the over-allotment option is fully exercised, which it intends to use for working capital and analytical testing.
Key figures
- Cash Position
- 6243000
- Offering Price
- 0.7151
- Shares Offered
- 17479373
- Shares Outstanding
- 26307211
- Net proceeds
- $11.0 million
- Warrant coverage
- 200%
- Accumulated deficit
- $482.6 million
- Net proceeds with oa
- $12.8 million
- Atm capacity remaining
- $47.0 million
- Two year warrant exercise price
- $0.7151
- Five year warrant exercise price
- $0.8224
Price after filing
Close on the filing date to close N calendar days later (from $0.70). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.